StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Investment analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

A number of other research analysts have also weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Thursday, February 6th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Trading Up 9.1 %

Shares of NYSE:VNRX opened at $0.63 on Friday. The stock has a market capitalization of $58.10 million, a PE ratio of -1.74 and a beta of 1.20. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.11. The firm has a fifty day moving average price of $0.62 and a 200 day moving average price of $0.65.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds acquired 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Guy Archibald Innes acquired 174,764 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the acquisition, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 358,266 shares of company stock worth $204,212 over the last ninety days. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Ground Swell Capital LLC grew its position in shares of VolitionRx by 78.8% in the 3rd quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock valued at $28,000 after acquiring an additional 20,249 shares during the period. Geode Capital Management LLC raised its stake in VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in VolitionRx in the 4th quarter worth about $29,000. Finally, Northern Trust Corp raised its position in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares in the last quarter. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.